The funding will speed up uMotif’s development and allow additional growth of its patient-centric and decentralised strategy to scientific research and allow growth into new research sorts and extra high-demand territories.
WHY IT MATTERS
Life sciences corporations are more and more adopting decentralised and digital research designs the place affected person consent and information is captured utilizing their very own units from their location.
That is in distinction to the centralised research wherein sufferers should go to a website, akin to a hospital, to submit their information.
uMotif powers decentralised and patient-centric approaches that enhance how engaged sufferers are, and due to this fact enhancing the possibilities of the research’s success. It additionally goals to scale back the burden on members and assist attain new affected person populations to extend research variety.
THE LARGER TREND
In June, uMotif raised $3.2 million in a brand new funding spherical led by impartial funding supervisor Albion Capital to develop operations, that are presently centered principally in the USA and Europe, into the Asia-Pacific area.
ON THE RECORD
Bruce Hellman, CEO and co-founder of London-based uMotif stated: “We’re excited to assist our clients implement patient-centred analysis designs by utilizing the uMotif platform to seize high-quality information.
“This new funding will quickly speed up our growth and can in the end assist our clients to get new therapies to sufferers quicker.”
Dr Andrew Elder, deputy managing accomplice at AlbionVC stated: “Now greater than ever, getting access to dependable affected person information throughout scientific trials is essential. uMotif’s platform is constructed with sufferers in thoughts; designed to assist lecturers, researchers and healthcare professionals to seize the very best quality information in a means that fits the members. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the pace and effectivity with which therapies can attain and assist tens of millions of sufferers.”